You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Subtyping of Invasive breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Invasive Trial (pyrotinib)

Not yet recruiting
  • Breast Cancer Invasive
  • (no location specified)
Jun 18, 2023

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,

Not yet recruiting
  • HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
  • (no location specified)
Nov 7, 2023

Molecular Subtyping of Triple-negative Breast Cancer and African

Not yet recruiting
  • Triple Negative Breast Cancer
  • DNA and whole transcriptome mRNA sequencing
  • (no location specified)
Oct 27, 2021

Breast Cancer Stage I Trial (Microwave ablation)

Not yet recruiting
  • Breast Cancer Stage I
  • Microwave ablation
  • (no location specified)
May 23, 2023

Breast Cancer Trial (Pyrotinib, Trastuzumab, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Apr 22, 2023

Breast Cancer Stage I Trial (Capecitabine,Pyrotinib)

Not yet recruiting
  • Breast Cancer Stage I
  • (no location specified)
May 7, 2023

Successful Microsurgical Breast Reconstruction in Minimally

Completed
  • Breast Reconstruction
  • Breast Cancer
    • Taoyuan, Taiwan
      ChangGungMH
    Jul 4, 2023

    Residual Disease in Breast Cancer Remission After Primary

    Recruiting
    • Breast Cancer
    • minimally invasive preoperative image-guided vacuum-assisted biopsy
    • Milan, Italy
      Fondazione IRCCS Istituto Nazionale dei Tumori
    Jul 10, 2023

    Breast Cancer, Metastatic Cancer Trial in Shanghai (SHR7390, Famitinib, SHR3162)

    Recruiting
    • Breast Cancer
    • Metastatic Cancer
    • Shanghai, Shanghai, China
      Cancer Hospital Affiliated to Fudan University
    Jul 22, 2022

    Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)

    Not yet recruiting
    • Triple-negative Breast Cancer
    • A1: SHR-A1811
    • +11 more
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 19, 2023

    Multiparametric MRI asNon-Invasive Biomarker of Tumor

    Recruiting
    • Breast Cancer
    • Triple-negative Breast Cancer
    • Tempus assay
    • +2 more
    • Nashville, Tennessee
      Vanderbilt University Medical Center
    Jan 10, 2023

    INnovative and Micro-INvasive TEchniques for Early

    Recruiting
    • Breast Cancer
    • Liquid biopsy and imaging
    • Aviano, Pordenone, Italy
      Centro di Riferimento Oncologico
    Apr 26, 2023

    Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast Trial in Scottsdale (LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • LS301-IT 0.025 mg/kg
    • +3 more
    • Scottsdale, Arizona
      Integro Theranostics Research Site #1
    Jun 2, 2023

    Tumor Biopsy in Creating Research Tissue Registry in

    Recruiting
    • Inflammatory Breast Carcinoma
    • +2 more
    • Biospecimen Collection
    • +3 more
    • Houston, Texas
    • +4 more
    Jan 6, 2023

    Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma Trial in Madison (18F-fluorofuranylnorprogesterone, Liquid Biopsy,

    Recruiting
    • Metastatic Cancer
    • +2 more
    • Madison, Wisconsin
      UW Carbone Cancer Center
    Oct 10, 2023

    Breast Cancer Trial in Salt Lake City (FNA and Core biopsy)

    Completed
    • Breast Cancer
    • FNA and Core biopsy
    • Salt Lake City, Utah
      Huntsman Cancer Hospital
    Oct 31, 2022

    Barriers Associated With Timely Adjuvant Chemotherapy

    Active, not recruiting
    • Invasive Breast Carcinoma
    • Interview
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 25, 2022

    Breast Cancer Trial in Chapel Hill (surgery, therapy, radiation therapy)

    Active, not recruiting
    Has Results
    • Breast Cancer
    • surgery
    • +2 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Dec 20, 2022

    Molecular Analysis of the Sloane Project

    Enrolling by invitation
    • DCIS
    • +3 more
      • London, United Kingdom
        King's College London
      May 11, 2023

      Breast Cancer, Breast Cancer Invasive Trial in Groningen (Fluorescence guided detection of tumor positive margins.)

      Not yet recruiting
      • Breast Cancer
      • Breast Cancer Invasive
      • Fluorescence guided detection of tumor positive margins.
      • Groningen, Netherlands
      • +1 more
      Jul 10, 2023

      Non-Invasive Magnetic Resonance Imaging and Magnetic Resonance

      Completed
      • Breast Cancer
      • Magnetic Resonance Imaging (MRI)
      • Magnetic Resonance Spectroscopy (MRS)
      • Houston, Texas
        University of Texas MD Anderson Cancer Center
      Oct 27, 2022

      Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant

      Not yet recruiting
      • Breast Cancer Triple Negative
      • +3 more
        • Atlanta, Georgia
          Emory University/Winship Cancer Institute
        May 18, 2023

        Depressive Symptoms, Cognitive Impairment Trial in Santiago De Compostela, Vigo (Transcranial Direct Current Stimulation,

        Not yet recruiting
        • Depressive Symptoms
        • Cognitive Impairment
        • Transcranial Direct Current Stimulation
        • +3 more
        • Santiago De Compostela, A Coruña, Spain
        • +1 more
        Sep 25, 2023

        Breast Cancer Trial in Galway (Wavelia #2)

        Recruiting
        • Breast Cancer
        • Wavelia #2
        • Galway, Ireland
          Galway University Hospital/Symptomatic Breast Unit
        Mar 11, 2023

        Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

        Not yet recruiting
        • Breast Cancer Invasive
        • +3 more
        • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
        • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
        • Guangzhou, Guangdong, China
          Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
        Nov 17, 2023